IGM Biosciences (IGMS) News Today $6.90 -0.15 (-2.13%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Igm biosciences principal accounting officer sells shares for $4,031December 20 at 9:43 PM | investing.comMary Beth Harler Sells 1,708 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) StockDecember 19 at 9:06 AM | insidertrades.comIGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 SharesIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) CEO Mary Beth Harler sold 1,708 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $7.48, for a total value of $12,775.84. Following the sale, the chief executive officer now owns 347,032 shares of the company's stock, valued at approximately $2,595,799.36. This represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.December 18 at 10:25 PM | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold rDecember 15, 2024 | marketbeat.comIGM Biosciences initiated with an Outperform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comBMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform RecommendationDecember 6, 2024 | msn.comIGM Biosciences (NASDAQ:IGMS) Shares Gap Up - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Shares Gap Up - Here's What HappenedDecember 6, 2024 | marketbeat.comBMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS)BMO Capital Markets began coverage on IGM Biosciences in a research report on Friday. They issued an "outperform" rating and a $21.00 target price on the stock.December 6, 2024 | marketbeat.comIGM Biosciences: Dizzying Number Of PivotsDecember 4, 2024 | seekingalpha.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 4.1% - Should You Sell?IGM Biosciences (NASDAQ:IGMS) Shares Down 4.1% - Here's What HappenedNovember 29, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Gap Down - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Shares Gap Down - Here's What HappenedNovember 22, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Hold" from BrokeragesIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and fouNovember 20, 2024 | marketbeat.comIGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimismNovember 15, 2024 | uk.investing.comRBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)November 12, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on IGM Biosciences (IGMS)November 12, 2024 | markets.businessinsider.comIGM Biosciences (NASDAQ:IGMS) Price Target Raised to $27.00Stifel Nicolaus lifted their price objective on shares of IGM Biosciences from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Monday.November 11, 2024 | marketbeat.comCautious Outlook for IGM Biosciences Amid Delayed Data and Financial AdjustmentsNovember 9, 2024 | markets.businessinsider.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 7.8% - Here's WhyIGM Biosciences (NASDAQ:IGMS) Trading Down 7.8% - Here's WhyNovember 8, 2024 | marketbeat.comIGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 8, 2024 | globenewswire.comIGM Biosciences (NASDAQ:IGMS) Stock, Option ChainNovember 6, 2024 | benzinga.comIGM Biosciences to Present at Three Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 3.7% - Time to Sell?IGM Biosciences (NASDAQ:IGMS) Shares Down 3.7% - Should You Sell?November 1, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Trading Up 7.7% - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Stock Price Up 7.7% - Should You Buy?October 28, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of "Hold" from AnalystsIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) has received a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have givenOctober 26, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 6.1% - Time to Sell?IGM Biosciences (NASDAQ:IGMS) Trading Down 6.1% - Should You Sell?October 21, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Price Target Raised to $20.00Royal Bank of Canada lifted their price target on IGM Biosciences from $17.00 to $20.00 and gave the company an "outperform" rating in a research report on Friday.October 18, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Up 8% - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Stock Price Up 8% - Should You Buy?October 17, 2024 | marketbeat.comIGM Biosciences, Inc. (NASDAQ:IGMS) Short Interest Down 23.9% in SeptemberIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 4,020,000 shares, a decline of 23.9% from the September 15th total of 5,280,000 shares. Based on an average daily trading volume, of 352,600 shares, the days-to-cover ratio is presently 11.4 days. Approximately 19.3% of the company's shares are short sold.October 15, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Down 5.5% - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Shares Down 5.5% - What's Next?October 15, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Trading 8.1% Higher - Here's WhyIGM Biosciences (NASDAQ:IGMS) Trading Up 8.1% - Should You Buy?October 11, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Down 3.7% - Time to Sell?IGM Biosciences (NASDAQ:IGMS) Stock Price Down 3.7% - Time to Sell?October 9, 2024 | marketbeat.comMarshall Wace LLP Has $737,000 Position in IGM Biosciences, Inc. (NASDAQ:IGMS)Marshall Wace LLP lifted its position in shares of IGM Biosciences, Inc. (NASDAQ:IGMS - Free Report) by 51.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 107,267 shares of the company's stock after buying an additional 36,491 sharesOctober 9, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Trading 10.1% Higher - Here's What HappenedIGM Biosciences (NASDAQ:IGMS) Trading Up 10.1% - Time to Buy?October 4, 2024 | marketbeat.comIGM Biosciences, Inc.: IGM Biosciences Announces Strategic Pivot to Focus Exclusively on AutoimmunityOctober 3, 2024 | finanznachrichten.deWedbush Comments on IGM Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:IGMS)IGM Biosciences, Inc. (NASDAQ:IGMS - Free Report) - Equities research analysts at Wedbush raised their Q3 2024 earnings per share estimates for IGM Biosciences in a report released on Tuesday, October 1st. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.83) per share foOctober 3, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Down 7.4% After Analyst DowngradeIGM Biosciences (NASDAQ:IGMS) Trading Down 7.4% After Analyst DowngradeOctober 2, 2024 | marketbeat.comJP Morgan Downgrades IGM Biosciences (IGMS)October 2, 2024 | msn.comTruist Securities Downgrades IGM Biosciences (IGMS)October 2, 2024 | msn.comIGM Biosciences downgraded to Hold, stock fallsOctober 1, 2024 | seekingalpha.comIGM Biosciences: Hold Rating Amidst Strategic Shift and Leadership ChangesOctober 1, 2024 | markets.businessinsider.comIGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismayOctober 1, 2024 | marketwatch.comIGM Biosciences (IGMS) Receives a Buy from WedbushOctober 1, 2024 | markets.businessinsider.comIGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEOOctober 1, 2024 | finance.yahoo.comGuggenheim Trims IGM Biosciences (NASDAQ:IGMS) Target Price to $20.00Guggenheim reduced their price target on IGM Biosciences from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday.October 1, 2024 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Shares Gap Down on Analyst DowngradeIGM Biosciences (NASDAQ:IGMS) Shares Gap Down Following Analyst DowngradeOctober 1, 2024 | marketbeat.comIGM Biosciences Shares Fall on Strategic Pivot to Autoimmunity, New CEOOctober 1, 2024 | marketwatch.comIGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionOctober 1, 2024 | msn.comIGM Biosciences (NASDAQ:IGMS) Downgraded to "Underweight" at JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of IGM Biosciences from a "neutral" rating to an "underweight" rating and decreased their price objective for the stock from $12.00 to $9.00 in a research report on Tuesday.October 1, 2024 | marketbeat.comIGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune DiseasesOctober 1, 2024 | barrons.comIGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Moderate Buy" by BrokeragesIGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to theOctober 1, 2024 | marketbeat.com Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. IGMS Media Mentions By Week IGMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IGMS News Sentiment▼0.390.61▲Average Medical News Sentiment IGMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IGMS Articles This Week▼63▲IGMS Articles Average Week Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVO News ARQT News NRIX News RCUS News KNSA News IMCR News OCUL News MESO News TVTX News NTLA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IGMS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IGMS Stock Alerts